BR112019006371A2 - compostos, composições farmacêuticas, uso de um composto ou composição e kits - Google Patents

compostos, composições farmacêuticas, uso de um composto ou composição e kits

Info

Publication number
BR112019006371A2
BR112019006371A2 BR112019006371A BR112019006371A BR112019006371A2 BR 112019006371 A2 BR112019006371 A2 BR 112019006371A2 BR 112019006371 A BR112019006371 A BR 112019006371A BR 112019006371 A BR112019006371 A BR 112019006371A BR 112019006371 A2 BR112019006371 A2 BR 112019006371A2
Authority
BR
Brazil
Prior art keywords
compound
kits
compounds
composition
pharmaceutical compositions
Prior art date
Application number
BR112019006371A
Other languages
English (en)
Inventor
Caravano Audrey
Ledoussal Benoît
Simon Christophe
Oliveira Chrystelle
Faivre Fabien
Chevreuil Francis
Le-Strat Frédéric
Le Fralliec Géraldine
Brias Julie
Barbion Julien
Farescour Laurence
Lecointe Nicolas
Lebel Rémi
Chasset Sophie
Vomscheid Sophie
Richard Sébastien
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutabilis filed Critical Mutabilis
Publication of BR112019006371A2 publication Critical patent/BR112019006371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

a invenção refere-se a um composto de fórmula (i) (i) e um racemato, um enantiômero, um diastereoisômero, um isômero geométrico ou um sal farmaceuticamente aceitável do mesmo e a sua utilização como agente antibacteriano.
BR112019006371A 2016-09-30 2017-09-29 compostos, composições farmacêuticas, uso de um composto ou composição e kits BR112019006371A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306261.5A EP3301094A1 (en) 2016-09-30 2016-09-30 Heterocyclic compounds and their use in preventing or treating bacterial infections
PCT/EP2017/074873 WO2018060481A1 (en) 2016-09-30 2017-09-29 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (1)

Publication Number Publication Date
BR112019006371A2 true BR112019006371A2 (pt) 2019-06-25

Family

ID=57130331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006371A BR112019006371A2 (pt) 2016-09-30 2017-09-29 compostos, composições farmacêuticas, uso de um composto ou composição e kits

Country Status (24)

Country Link
US (1) US10722520B2 (pt)
EP (3) EP3301094A1 (pt)
JP (2) JP7089508B2 (pt)
KR (1) KR102691642B1 (pt)
CN (2) CN109906226B (pt)
AR (1) AR109774A1 (pt)
AU (1) AU2017335222C1 (pt)
BR (1) BR112019006371A2 (pt)
CA (1) CA3038221A1 (pt)
CL (1) CL2019000857A1 (pt)
DK (1) DK3519411T3 (pt)
ES (1) ES2927528T3 (pt)
HR (1) HRP20220831T1 (pt)
HU (1) HUE059938T2 (pt)
IL (1) IL265676B (pt)
LT (1) LT3519411T (pt)
MX (1) MX2019003545A (pt)
PL (1) PL3519411T3 (pt)
PT (1) PT3519411T (pt)
RS (1) RS63473B1 (pt)
SI (1) SI3519411T1 (pt)
TW (1) TWI801353B (pt)
WO (1) WO2018060481A1 (pt)
ZA (1) ZA201901963B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
US20240228480A1 (en) * 2021-01-21 2024-07-11 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
GEP20094751B (en) * 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8138189B2 (en) 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9487474B2 (en) 2012-06-04 2016-11-08 Elkimia, Inc. Imino compounds as protecting agents against ultraviolet radiations
US9365526B2 (en) 2012-12-31 2016-06-14 Sun Pharmaceutical Industries Limited Process for the preparation of dasatinib and its intermediates
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10857138B2 (en) * 2014-04-18 2020-12-08 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EA033829B1 (ru) * 2014-11-17 2019-11-29 Entasis Therapeutics Ltd Комбинированная терапия для лечения устойчивых бактериальных инфекций
CN105704828A (zh) * 2014-11-25 2016-06-22 中兴通讯股份有限公司 一种资源调度的方法和装置
AU2016257338B2 (en) 2015-05-07 2020-03-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
EP3301094A1 (en) 2018-04-04
SI3519411T1 (sl) 2022-08-31
CN113929680A (zh) 2022-01-14
EP3519411B1 (en) 2022-06-22
ZA201901963B (en) 2021-01-27
ES2927528T3 (es) 2022-11-08
PT3519411T (pt) 2022-08-25
RS63473B1 (sr) 2022-08-31
PL3519411T3 (pl) 2022-08-22
RU2019109177A (ru) 2020-09-30
AU2017335222A2 (en) 2019-05-09
CL2019000857A1 (es) 2019-08-09
AU2017335222B2 (en) 2021-07-15
DK3519411T3 (da) 2022-07-11
RU2019109177A3 (pt) 2020-11-30
JP7089508B2 (ja) 2022-06-22
HRP20220831T1 (hr) 2022-09-30
LT3519411T (lt) 2022-09-12
AR109774A1 (es) 2019-01-23
CN109906226A (zh) 2019-06-18
AU2017335222C1 (en) 2022-01-20
AU2017335222A1 (en) 2019-04-11
CA3038221A1 (en) 2018-04-05
JP2019530690A (ja) 2019-10-24
CN109906226B (zh) 2021-11-02
US20190224210A1 (en) 2019-07-25
IL265676B (en) 2021-12-01
TWI801353B (zh) 2023-05-11
WO2018060481A1 (en) 2018-04-05
KR20190065326A (ko) 2019-06-11
TW201815791A (zh) 2018-05-01
JP2022097520A (ja) 2022-06-30
IL265676A (en) 2019-05-30
EP3519411A1 (en) 2019-08-07
EP4086255A1 (en) 2022-11-09
HUE059938T2 (hu) 2023-01-28
MX2019003545A (es) 2019-06-17
KR102691642B1 (ko) 2024-08-05
US10722520B2 (en) 2020-07-28

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2020000023A (es) Nuevos derivados de quinolina
GEP20237506B (en) Pcsk9 antagonist compounds
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CO2019014484A2 (es) Nuevos derivados de azaquinolina
UY37201A (es) Nuevos derivados de pirazolopirimidina
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
EA201892822A1 (ru) Новые антибактериальные соединения
DOP2016000253A (es) Nuevos compuestos
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112018074985A2 (pt) composições antibacterianas
EA202190356A1 (ru) Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
BR112018008006A2 (pt) composto de piranodipiridina
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112019006371A2 (pt) compostos, composições farmacêuticas, uso de um composto ou composição e kits

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]